Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
Public ClinicalTrials.gov record NCT00572559. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open Label, Multi-Center Clinical Trial, Comparing Microbiologic Response To Linezolid And Vancomycin In Ventilator-Associated Pneumonia (VAP) Due To Methicillin Resistant Staphylococcus Aureus (MRSA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours. Methicillin-resistant Staphylococcus aureus (MRSA) is the cause of late onset VAP in up to about 30% of cases in US hospitals. Ineffective treatment of MRSA VAP clearly leads to prolonged mechanical ventilation and is probably associated with higher mortality. The purpose of this protocol is to directly compare linezolid and vancomycin specifically for MRSA VAP.
Study identification
- NCT ID
- NCT00572559
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 149 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2002
- Primary completion
- Not listed
- Completion
- Dec 31, 2004
- Last update posted
- Jun 8, 2010
2002 – 2005
United States locations
- U.S. sites
- 36
- U.S. states
- 13
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | 85006 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85012 | — |
| Pfizer Investigational Site | Palm Springs | California | 92262 | — |
| Pfizer Investigational Site | Rancho Mirage | California | 92270 | — |
| Pfizer Investigational Site | Redlands | California | 92373 | — |
| Pfizer Investigational Site | Sacramento | California | 95819 | — |
| Pfizer Investigational Site | Sacramento | California | 95829 | — |
| Pfizer Investigational Site | Norwalk | Connecticut | 06850 | — |
| Pfizer Investigational Site | Waterbury | Connecticut | 06708 | — |
| Pfizer Investigational Site | Waterbury | Connecticut | 06721 | — |
| Pfizer Investigational Site | Augusta | Georgia | 30909 | — |
| Pfizer Investigational Site | Decatur | Georgia | 30033 | — |
| Pfizer Investigational Site | North East Atlanta | Georgia | 30308 | — |
| Pfizer Investigational Site | North East Atlanta | Georgia | 30322 | — |
| Pfizer Investigational Site | North East Atlanta | Georgia | 30329 | — |
| Pfizer Investigational Site | ‘Ewa Beach | Hawaii | 96706 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60612 | — |
| Pfizer Investigational Site | Peoria | Illinois | 61603 | — |
| Pfizer Investigational Site | Peoria | Illinois | 61636 | — |
| Pfizer Investigational Site | Peoria | Illinois | 61637 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40536 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40206 | — |
| Pfizer Investigational Site | Buffalo | New York | 14215 | — |
| Pfizer Investigational Site | Cortland Manor | New York | 10567 | — |
| Pfizer Investigational Site | Jamaica | New York | 11418 | — |
| Pfizer Investigational Site | The Bronx | New York | 10467 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45267-0559 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38103 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38104 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38163 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37212-3375 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Spokane | Washington | 99204 | — |
| Pfizer Investigational Site | Spokane | Washington | 99216 | — |
| Pfizer Investigational Site | Spokane | Washington | 99220 | — |
| Pfizer Investigational Site | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00572559, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2010 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00572559 live on ClinicalTrials.gov.